Table 6.

Economic evaluation results: costs, effects and ICERs

Intervention strategies	Costs (€/patient)		Effect (per patient)		ICER
	Mean	[95% CI]	Mean	[95% CI]	Mean	[95% CI]
CEA			% death/renal problem (30-day FU)		€/case
CO-PCI	25,400	[22,600, 28,200]	0.541	[0.457, 0.615]
MV-PCI	24,500	[21,800, 27,500]	0.447	[0.393, 0.5]
CO-PCI vs. MV-PCI	841	[− 3360, 4780]	0.0933	[0.0225, 0.159]	9010	[− 45,400, 83,200]
CUA (1-year FU)			QALYs		€/QALY
CO-PCI	25,400	[22,600, 28,200]	0.398	[0.319, 0.478]
MV-PCI	24,500	[21,800, 27,500]	0.34	[0.285, 0.394]
CO-PCI vs. MV-PCI	841	[− 3360, 4780]	0.0577	[− 0.00275, 0.114]	14,600	[− 111,000, 178,000]
CUA (lifelong)			QALYs		€/QALY
CO-PCI	27,200	[23,500, 37,700]	2.94	[1.09, 5.49]
MV-PCI	25,100	[22,400, 29,,400]	2.64	[0.951, 4.83]
CO-PCI vs. MV-PCI	2060	[− 2370, 10,500]	0.293	[− 0.69, 1.51]	7010	[− 92,200, 107,000]

Effectiveness measure for CEA is % reduction of composite outcome death or renal-replacement therapy at 30-day follow-up. Figures are rounded to 3 significant figures

CO-PCI culprit only percutaneous coronary intervention, MV-PCI multivessel percutaneous coronary intervention.